Further Penetration of Overseas Markets and Winning Orders in Asia
First written in FY2016-Q4. 15 of 40 entries say "Restated". Latest entry: FY2026.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2025.
The whole theme swung hardest in 2020: 1 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Sales from the life science research support services business declined substantially because of a decrease in large projects in the domestic academia sector and a significant decline in overseas sales due to lower overall market demand, among other factors, to ¥930.832 million, down 18.6% from the previous consolidated fiscal year.」
Sales from the life science research support services business, including overseas markets, declined 18.6% year on year because of lower overall market demand and other factors. - FY2026-H1WorsenedAnnual report
「Sales in the US fell below the previous year, partly because of the impact of the government shutdown during the interim period, for the life science research support services business.」
US sales fell below the previous year because of the government shutdown and other factors, indicating deterioration in overseas market performance. - FY2025-H1WorsenedAnnual report
「In the US and Europe, orders struggled in both academia and pharmaceuticals, and the recording of sales was also delayed, resulting in a substantial decline in sales across the region.」
In the US and Europe, orders struggled in pharmaceuticals as well as academia, while delays in recording sales resulted in a substantial decline in sales across the region. - FY2024AdvancedAnnual report
「The pharmaceutical sector drove overseas operations through orders from global pharmaceutical companies, resulting in a substantial increase in sales.」
Overseas sales in the advanced research and development support business increased 36.3%, from ¥218.970 million to ¥298.399 million. Orders from global pharmaceutical companies indicated specific progress in the company’s overseas operations. - FY2024-Q3AdvancedAnnual report
「Overseas pharmaceutical-sector sales increased and remained firm, but total sales declined as a result of lower domestic sales.」
The company reported increased and firm pharmaceutical-sector sales overseas, indicating specific progress in its overseas operations. - FY2024-Q2RestatedAnnual report
「Although overseas sales were roughly at the previous-year level, total sales declined substantially as a result of lower domestic sales.」
While overseas sales remained roughly at the previous-year level, lower domestic sales were a factor in the decline in sales from the advanced research and development support business. - FY2024-Q1WorsenedAnnual report
「In the US and Europe, sales declined because there were no sales from projects comparable to the large-scale and custom projects recorded in the same period of the previous year.」
In the US and Europe, there were no sales comparable to the large-scale and custom projects recorded in the same period of the previous year, resulting in a decline in overseas sales. - FY2023AdvancedAnnual report
「(Of which, overseas sales) ¥191.630 million ¥218.970 million 14.3%」
Overseas sales in the advanced research and development support business increased from ¥191.630 million to ¥218.970 million, indicating progress in the company’s overseas operations. - FY2023-Q3AdvancedAnnual report
「Sales of contract metabolite analysis services increased substantially in the US and Europe.」
In overseas markets, sales of contract metabolite analysis services in the US and Europe increased substantially. - FY2023-Q2AdvancedAnnual report
「Demand for contract metabolite analysis services is expanding, particularly in the US and Europe.」
The company reported expanding demand for contract metabolite analysis services in the US and Europe, particularly in overseas markets. - FY2023-Q1AdvancedAnnual report
「In this business segment, high-sensitivity comprehensive analysis services remained firm both in Japan and overseas, and sales increased substantially, mainly in the academia sector.」
High-sensitivity comprehensive analysis services remained firm in Japan and overseas, and sales from the advanced research and development support business, including overseas sales, increased. - FY2022WorsenedAnnual report
「In the overseas business, US orders from academia and pharmaceutical companies remained firm, and sales in the food sector also increased as the use of metabolomics in cultured-meat research and development expanded further. In Asia-Pacific, however, orders and sales declined substantially because the company was unable to conduct sufficient sales activities amid the impact of COVID-19.」
The US business remained firm in the academia, pharmaceutical and food sectors, while sales activities, orders and sales declined in Asia-Pacific because of the impact of COVID-19. - FY2022-Q3WorsenedAnnual report
「In this business segment, orders remained strong across all fields: academia, pharmaceuticals, food and chemicals. Orders from academia and pharmaceutical companies increased substantially, driven in particular by expanded sales of high-sensitivity comprehensive analysis services and lipid analysis services, resulting in a substantial increase in domestic sales. Orders in the US also remained strong, as in Japan, but sales declined because of delays in the arrival of measurement samples and other factors. In addition, overseas sales declined because of the renewed spread of COVID-19 in Asia-Pacific and other factors.」
Orders in Japan and the US were strong, while overseas sales declined because of delays in the arrival of measurement samples and the renewed spread of COVID-19 in Asia-Pacific. - FY2022-Q1WorsenedAnnual report
「Overseas, US sales remained at roughly the previous-year level, but total overseas sales declined because of the renewed spread of COVID-19 in Asia-Pacific and reduced activity related to the closure of the European subsidiary.」
While US sales remained at roughly the previous-year level, total overseas sales declined because of the renewed spread of COVID-19 in Asia-Pacific and reduced activity related to the closure of the European subsidiary. - FY2021ReframedAnnual report
「Overseas, US sales increased as orders from academia, drug-discovery ventures and agritech companies grew, and sales remained firm. Although sales from the European business declined because of repeated lockdowns and other effects of the COVID-19 pandemic, total overseas sales increased. As disclosed in April 2021, the company decided to close the European business and is currently proceeding with the closure in accordance with local law.」
The company’s overseas operations changed to a structure involving increased orders in the US and the closure of its European business. - FY2021-Q3SoftenedAnnual report
「Subsequently, after considering the stagnation of economic activity in Europe caused by the COVID-19 pandemic and the financial position of Human Metabolome Technologies Europe B.V., among other factors, the company examined the optimal business structure for the European market going forward. As a result, it decided to centralize management through its US subsidiary, close its sales base in Europe, and dissolve and liquidate the company.」
The company indicated a policy of closing its European sales base and shifting to centralized management through its US subsidiary, reducing its previous European operating structure. - FY2021-Q2AdvancedAnnual report
「In this business segment, the Group conducted sales activities centred on the use of the Web. As a result, sales increased significantly in the domestic academic sector and in the overseas US pharmaceutical sector.」
Sales in the US pharmaceutical sector increased substantially, indicating specific progress in overseas market development. - FY2021-Q1AdvancedAnnual report
「In this business segment, the company’s sales activities, centered on the use of the web, resulted in a substantial increase in sales in the domestic food sector and a substantial increase in sales in the US pharmaceutical sector overseas.」
The company reported a substantial increase in sales in the US pharmaceutical sector overseas, indicating specific progress in its overseas expansion. - FY2020RestatedAnnual report
「Overseas, the company worked mainly in the US and Europe to review its pricing strategy and also actively pursued market expansion activities in Asia.」
The company continues to expand in the US, Europe and Asia through its overseas sales structure, pricing strategy and distributors. - FY2020RestatedAnnual report
「Overseas, the company worked mainly in the US and Europe to review its pricing strategy and also actively pursued market expansion activities in Asia.」
The company continues to review its pricing strategy in the US and Europe and pursue market expansion activities in Asia. - FY2020-Q3RestatedAnnual report
「Overseas, the Group worked to strengthen its sales organisation, including by reviewing its pricing strategy and making effective use of distributors, mainly in the US and Europe, while also actively pursuing activities to expand the Asian market.」
The company continues to review its pricing strategy in the US and Europe, use distributors, strengthen its sales structure, and pursue market expansion activities in Asia. - FY2020-Q2RestatedAnnual report
「Overseas, the Group worked to strengthen its sales organisation, including by reviewing its pricing strategy and making effective use of distributors, mainly in the US and Europe, while also actively pursuing activities to expand the Asian market.」
The company continues to review its pricing strategy in the US and Europe, use distributors, strengthen its sales structure, and pursue market expansion activities in Asia. - FY2020-Q1RestatedAnnual report
「Overseas, the Group worked to strengthen its sales organisation, including by reviewing its pricing strategy and making effective use of distributors, mainly in the US and Europe, while also actively pursuing activities to expand the Asian market.」
The company is reviewing its pricing strategy and expanding the use of distributors in the US and Europe, strengthening its sales structure while continuing market expansion activities in Asia. No specific order results or completed milestones are reported. - FY2019RestatedAnnual report
「Overseas, the Group strengthened its efforts to acquire large customers, mainly in the US, while also actively pursuing activities to expand the European and Asian markets.」
Continues activities to expand overseas markets in the US, Europe and Asia. - FY2019-Q3RestatedAnnual report
「Overseas, the Group strengthened its efforts to secure large projects, mainly in the US, while also actively pursuing activities to expand the European and Asian markets.」
Continues to secure large projects, mainly in the US, and pursue activities to expand the European and Asian markets. - FY2019-Q2RestatedAnnual report
「Overseas, the Group strengthened its efforts to secure large projects, mainly in the US, while also actively pursuing activities to expand the European and Asian markets.」
Continues to secure large projects, mainly in the US, and pursue activities to expand the European and Asian markets. - FY2019-Q1RestatedAnnual report
「Overseas, the Group strengthened its efforts to secure large projects, mainly in the US, while also actively pursuing activities to expand the European and Asian markets.」
Continues to state its efforts to secure large projects, mainly in the US, and activities to expand the European and Asian markets. - FY2018-Q4RestatedAnnual report
「Overseas, the Group strengthened its efforts to secure large projects, mainly in the US, while also actively pursuing activities to expand the European and Asian markets.」
Continues to state its efforts to secure large projects, mainly in the US, and activities to expand the European and Asian markets. - FY2018-Q2RestatedAnnual report
「Overseas, the Group also worked to secure large projects. Orders from the pharmaceutical and clinical sectors increased, mainly in the US, while it also actively pursued initiatives to expand the European and Asian markets.」
Continues to secure orders in the pharmaceutical and clinical sectors, mainly in the US, and pursue activities to expand the European and Asian markets. - FY2018-Q1RestatedAnnual report
「Overseas, the Group also worked to secure large projects. Orders from the pharmaceutical and clinical sectors increased, mainly in the US, while it also actively pursued initiatives to expand the European and Asian markets.」
Continues to state the increase in orders mainly in the US and activities to expand the European and Asian markets. - FY2017-Q4AdvancedAnnual report
「Overseas, the Group also worked to secure large projects. Orders from the pharmaceutical and clinical sectors increased, mainly in the US, while it also actively pursued initiatives to expand the European and Asian markets.」
It was stated that orders from the pharmaceutical and clinical sectors, mainly in the US, had increased and that activities to expand the European and Asian markets had also intensified. - FY2017RaisedAnnual report
「The Group plans to accelerate its overseas expansion by strengthening sales activities in North America and the Asia-Pacific region and making a full-scale entry into Europe.」
In addition to securing orders in the US and Asia, the Group has newly set out a full-scale entry into Europe, expanding the scope of its overseas operations. - FY2017-Q2RestatedAnnual report
「Overseas, orders from the pharmaceutical and clinical sectors increased, partly because the Group increased its sales staff in the US, while it also focused on securing orders from Asian markets, including South Korea and Singapore.」
It reiterated the increase in orders supported by the US sales organisation and the focus on securing orders in Asian markets, including South Korea and Singapore. - FY2017-Q1RestatedAnnual report
「Overseas, orders from the pharmaceutical and clinical sectors increased, partly because the Group increased its sales staff in the US, while it also focused on securing orders from Asian markets, including South Korea and Singapore.」
It reiterated the increase in orders supported by the US sales organisation and the focus on securing orders in Asian markets, including South Korea and Singapore. - FY2016-Q4First statedAnnual report
「Overseas, orders from the pharmaceutical and clinical sectors increased, partly because the Group increased its sales staff in the US, while it also focused on securing orders from Asian markets, including South Korea and Singapore.」
It stated that the Group had increased its US sales staff, expanded orders from the pharmaceutical and clinical sectors, and focused on securing orders in South Korea and Singapore.